Effect of Clinical and Treatment Factors on Survival Outcomes of Triple Negative Breast Cancer Patients

References

• Australian Institute of Health and Welfare (AIHW). Australian Cancer Incidence and Mortality (ACIM) Books: All Cancers Combined. Canberra; 2017Accessed 212, 2017.
   Google Scholar
• OnitiloAA, EngelJM, GreenleeRT, MukeshBN. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res. 2009;7:4–13. doi:10.3121/cmr.2009.82519574486
   PubMedGoogle Scholar
• CareyL, WinerE, VialeG, CameronD, GianniL. Triple-negative breast cancer: disease entity or title of convenience?Nat Rev Clin Oncol. 2010;7:683–692. doi:10.1038/nrclinonc.2010.15420877296
   PubMed Web of Science ®Google Scholar
• OakmanC, VialeG, Di LeoA. Management of triple negative breast cancer. Breast. 2010;19:312–321. doi:10.1016/j.breast.2010.03.02620382530
   PubMed Web of Science ®Google Scholar
• PalSK, ChildsBH, PegramM. Triple-negative breast cancer: unmet medical needs. Breast Cancer Res Treat. 2011;125:627–636. doi:10.1007/s10549-010-1293-121161370
   PubMed Web of Science ®Google Scholar
• PalSK, MortimerJ. Triple-negative breast cancer: novel therapies and new directions. Maturitas. 2009;63:269–274. doi:10.1016/j.maturitas.2009.06.01019632796
   PubMed Web of Science ®Google Scholar
• NaherS, TognelaA, MoylanE, AdamsDH, KielyBE. Patterns of care and outcomes among triple negative early breast cancer patients in South Western Sydney. Intern Med J. 2018;48:567–572. doi:10.1111/imj.1362828967175
   PubMed Web of Science ®Google Scholar
• KimJE, AhnHJ, AhnJH, et al. Impact of triple-negative breast cancer phenotype on prognosis in patients with stage I breast cancer. J Breast Cancer. 2012;15:197–202. doi:10.4048/jbc.2012.15.2.19722807937
   PubMed Web of Science ®Google Scholar
• MacBrideMB, NealL, DilaveriCA, et al. Factors associated with surgical decision making in women with early-stage breast cancer: a literature review. J Womens Health (Larchmt). 2013;22:236–242. doi:10.1089/jwh.2012.396923428286
   PubMed Web of Science ®Google Scholar
• KimHA, SeongMK, KimEK, et al. Evaluation of the survival benefit of different chemotherapy regimens in patients with T1-2N0 triple-negative breast cancer. J Breast Cancer. 2015;18:271–278. doi:10.4048/jbc.2015.18.3.27126472978
   PubMed Web of Science ®Google Scholar
• KeatingNL, LandrumMB, BrooksJM, et al. Outcomes following local therapy for early-stage breast cancer in non-trial populations. Breast Cancer Res Treat. 2011;125:803–813. doi:10.1007/s10549-010-0865-420376555
   PubMed Web of Science ®Google Scholar
• EviQ Cancer Treatments Online. Breast invasive cancer adjuvant EBRT conventional whole breast. Last modified 28 April 2016 Available from:https://www.eviq.org.au/radiation-oncology/breast/1922-breast-invasive-cancer-adjuvant-ebrt-conventi. Accessed 818, 2016.
   Google Scholar
• EviQ Cancer Treatments Online. Breast invasive cancer adjuvant EBRT hypofractionation whole breast. Last modified 28 April 2016 Available from:https://www.eviq.org.au/radiation-oncology/breast/1923-breast-invasive-cancer-adjuvant-ebrt-hypofrac. Accessed 818, 2016.
   Google Scholar
• Cancer Australia. Recommendations for Use of Hypofractionated Radiotherapy for Early (Operable) Breast Cancer – A Clinical Practice Guideline. Surry Hills, NSW; 2015.
   Google Scholar
• ShaitelmanSF, SchlembachPJ, ArzuI, et al. Acute and short-term toxic effects of conventionally fractionated vs hypofractionated wholebreast irradiation: a randomized clinical trial. JAMA Oncol. 2015;1:931–941. doi:10.1001/jamaoncol.2015.266626247543
   PubMed Web of Science ®Google Scholar
• NitscheM, DunstJ, CarlUM, HermannRM. Emerging role of hypofractionated radiotherapy with simultaneous integrated boost in modern radiotherapy of breast cancer. Breast Care (Basel). 2015;10:320–324. doi:10.1159/00043695126688679
   PubMed Web of Science ®Google Scholar
• DelaneyGP, GandhidasanS, WaltonR, TerlichF, BakerD, CurrowD. The pattern of use of hypofractionated radiation therapy for early-stage breast cancer in New South Wales, Australia, 2008 to 2012. Int J Radiat Oncol Biol Phys. 2016;96:266–272. doi:10.1016/j.ijrobp.2016.05.01627473814
   PubMed Web of Science ®Google Scholar
• ChenQ-X, Wang-X-X, LinP-Y, et al. The different outcomes between breast-conserving surgery and mastectomy in triple-negative breast cancer: a population-based study from the SEER 18 database. Oncotarget. 2017;8:4773–4780. doi:10.18632/oncotarget.1397627999201
   PubMedGoogle Scholar
• WangL, OuyangT, WangT, et al. Safety of breast-conserving treatment for triple-negative breast cancer. Zhonghua Wai Ke Za Zhi. 2015;53:947–952.26850668
   PubMedGoogle Scholar
• FastnerG, Hauser-kronbergerC, ModerA, et al. Survival and local control rates of triple-negative breast cancer patients treated with boost-IOERT during breast-conserving surgery. Strahlenther Onkol. 2016;192:1–7. doi:10.1007/s00066-015-0895-226403912
   PubMed Web of Science ®Google Scholar
• Wang-X-X, JiangY-Z, Li-J-J, SongC-G, ShaoZ-M. Effect of nodal status on clinical outcomes of triple-negative breast cancer: a population-based study using the SEER 18 database. Oncotarget. 2016;7:46636–46645. doi:10.18632/oncotarget.943227203673
   PubMedGoogle Scholar
• StewardL, ConantL, GaoF, MargenthalerJA. Predictive factors and patterns of recurrence in patients with triple negative breast cancer. Ann Surg Oncol. 2014;21:2165–2171. doi:10.1245/s10434-014-3546-424558065
   PubMed Web of Science ®Google Scholar
• OvcaricekT, FrkovicSG, MatosE, MozinaB, BorstnarS. Triple negative breast cancer – prognostic factors and survival. Radiol Oncol. 2011;45:46–52. doi:10.2478/v10019-010-0054-422933934
   PubMed Web of Science ®Google Scholar
• RakhaEA, El-sayedME, GreenAR, LeeAH, RobertsonJF, EllisIO. Prognostic markers in triple-negative breast cancer. Cancer. 2007;109:25–32. doi:10.1002/cncr.2238117146782
   PubMed Web of Science ®Google Scholar
• LiaoGS, ChouYC, HsuHM, DaiMS, YuJC. The prognostic value of lymph node status among breast cancer subtypes. Am J Surg. 2015;209:717–724. doi:10.1016/j.amjsurg.2014.05.02925192588
   PubMed Web of Science ®Google Scholar
• NishimuraR, ArimaN. Is triple negative a prognostic factor in breast cancer?Breast Cancer. 2008;15:303–308. doi:10.1007/s12282-008-0042-318369692
   PubMed Web of Science ®Google Scholar
• ShibutaK, UeoH, FurusawaH, et al. The relevance of intrinsic subtype to clinicopathological features and prognosis in 4266 Japanese women with breast cancer. Breast Cancer. 2011;18:292–298. doi:10.1007/s12282-010-0209-620571962
   PubMed Web of Science ®Google Scholar
• HavilandJS, OwenJR, DewarJA, et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol. 2013;14:1086–1094. doi:10.1016/S1470-2045(13)70386-324055415
   PubMed Web of Science ®Google Scholar
• ParkJH, AhnJ-H, KimS-B. How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies. ESMO Open. 2018;3(Suppl 1):e000357. doi:10.1136/esmoopen-2018-00035729765774
   PubMed Web of Science ®Google Scholar